I D
× COMMENTARY
Dorothy LozowskiLooking ahead
This has certainly been a year to remember, and as…
COVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chemical EngineeringChementator Briefs
DESALINATION The challenge for large-scale desalination is to improve the…
BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILEENVIRONMENTAL MANAGEREQUIPMENT & SERVICESFOCUS
Focus on Pumps
New sizes available for progressive-cavity pumps NEMO progressive-cavity pumps with…
NEW PRODUCTS + Show More

Comment uncategorized

MilliporeSigma launches membrane-manufacturing facility in Darmstadt

By Mary Page Bailey |

MilliporeSigma (Burlington, Mass.) celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany. With the new facility, the company plans to expand manufacturing of Millipore Express membranes, which are critical components in Millipore Express filters and help ensure the sterility of biological drug products. The project with a volume of more than $165 million is part of the $1.2 billion investment in its global headquarters until 2025 that MilliporeSigma’s parent company, Merck KGaA, Darmstadt, Germany, announced last year.

MilliporeSigma plays a pivotal role in the growing biopharmaceutical membrane market. This investment demonstrates the company’s commitment to advancing the production of new therapies and its support for bringing important drugs to market.

“As a science and technology company, we want to pave the way for new therapies and contribute to improving the lives of patients around the world. With this strategically important production facility for our Life Science business sector, we are investing in future technologies, enabling additional growth and creating new jobs at our company’s global headquarters,” said Stefan Oschmann, chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany.

Chris Ross, interim CEO of MilliporeSigma, added: “As a world-leading life science tools and solutions provider, we play a pivotal role in the growing biopharmaceutical membrane market. This investment increases our membrane manufacturing capacity and allows for more supply chain diversification. It also demonstrates our commitment to advancing the production of new therapies and our support for bringing important drugs to market.”

The new membrane production plant is expected to create approximately 55 new jobs. Construction began in March and is expected to be completed in 2022, followed by production process validation and commercialization. The new, four-story membrane plant will incorporate immersion membrane casting equipment, quality control laboratories and offices.

Express membranes from MilliporeSigma will be manufactured at the new facility in Darmstadt, then processed into filters for pharmaceutical production at MilliporeSigma’s existing device Center of Excellence in Jaffrey, New Hampshire.

Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Video - Do you really need a thermowell?
The influence of IIoT in the dewatering process step of pigment production
The Big 6 level measurement technologies, where to use them and why
Top five technologies for drying in chemical applications
Crude distillation unit (CDU) optimization

View More